Table 1 Summary of anti-RR autoantibody reactivity in HCV patients treated with interferon-α/ribavirin and telaprevir
Parameters | Total patients (n = 52) | Anti-RR-positive patients (n = 10) | Anti-RR-negative patients (n = 42) | p value |
|---|---|---|---|---|
Male | 36 (69%) | 7 (70%) | 29 (69%) | NS |
Female | 16 (31%) | 3 (30%) | 13 (31%) | NS |
Age (years) ± SD | 54 ± 9 | 53 ± 14 | 54 ± 8 | NS |
Genotype 1a# | 12 (23%) | 3 (30%) | 9 (21%) | NS |
Genotype 1b# | 39 (75%) | 7 (70%) | 32 (76%) | NS |
Previous IFN/RBV | 32 (62%) | 10 (100%) | 22 (52%) | <0.01 |
Treatment outcome | ||||
SVR, no side effects | 35 (67%) | 6 (60%) | 29 (69%) | NS |
SVR, but side effects | 5 (10%) | 1 (10%) | 4 (10%) | NS |
SVR, combined | 40 (77%) | 7 (70%) | 33 (79%) | NS |
Relapse | 5 (10%) | 3 (30%) | 2 (5%) | <0.05 |
No response | 7 (13%) | 0 (0%) | 7 (17%) | NS |
Fisher–Freeman–Halton exact test | ||||
Anti-RR positive vs. anti-RR negative, with SVR separated | NS | |||
Anti-RR positive vs. anti-RR negative, with SVR combined | <0.05 | |||